Search
  • ryanjamesjessup

Biomarker Consultants | Late Phase

Updated: Apr 28

In late-phase trials, there are two types of biomarkers used to evaluate or predict outcomes - prognostic and predictive.


Overall, molecular and functional biomarker development remains a very active area of current investigation and commercialization. These biomarkers can serve as surrogate endpoints for therapeutic efficacy and are increasingly viewed by the Food and Drug Administration as highly desirable.


Attractive features are:

  • Reduced trial size,

  • Shortened completion time, and

  • Reduced costs

Biomarkers can also be extended to use as diagnostic agents, either as stand-alone probes or in combination with therapeutic drugs in order to stratify patients for treatment and outcome monitoring.


Also, previously developed and validated biomarkers can be applied to new therapeutic trials in order to reduce sample size and shorten the time to conduct a trial. Therefore, objective, quantifiable biomarker endpoints can significantly reduce data variability and generate early, statistically significant therapeutic effects and imaging standardization is essential for achieving this goal.


BioMolecular Imaging can identify the optimal imaging technology for you and assist your company in all aspects of standardized image acquisition and analysis.


Please read these articles by the Founder of BioMolecular Imaging, Dr. J. James Frost:

About BioMolecular Imaging


BioMolecular Imaging (BMI Consultants) is a molecular imaging and clinical trial consultancy owned and operated by Dr. J. James Frost M.D./Ph.D out of Baltimore Maryland. BMI has been involved with clinical, therapeutic & diagnostic imaging focused on Oncology, Brain, Biomarkers, Cardiology and Central Image Interpretations for over 20 years.


To learn more about BioMolecular Imaging, please visit https://www.BioMolecularImaging.com or connect with:


SoundCloud - https://soundcloud.com/BioMolecular-Imaging

Facebook - https://www.facebook.com/BMIConsultants

Twitter - https://twitter.com/BMIConsultants

LinkedIn - https://www.linkedin.com/company/BioMolecular-Imaging

YouTube - https://www.youtube.com/channel/UCkdv6cOQ8HunygNTtU66s2w


Copyright © 2022 BioMolecular Imaging


BioMolecular Imaging is a registered trademark of BioMolecular Imaging D.B.A. BMI Consultants

18 views0 comments

Recent Posts

See All

Diagnostic imaging is a core competency of BioMolecular Imaging - and is the approach of imaging the human body to analyze and form medical intervention, especially when viewing the function of organs

Imaging in therapeutic trials is the key process in expanding the understanding, methodology and metrics which are required to make determinations in drug targeting and efficacy. This spans most all i

A very active area of current investigation and commercialization is molecular and functional biomarker development. These biomarkers can serve as surrogate endpoints for therapeutic efficacy and are